Pacific Biosciences Of California (PACB) Net Cash Flow (2010 - 2026)

Pacific Biosciences Of California's Net Cash Flow history runs 17 years deep, the most recent figure standing at -$7.4 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 335.73% year-over-year to -$7.4 million; the TTM figure through Mar 2026 stood at -$2.9 million (up 84.63% YoY), while the FY2025 annual figure was $7.7 million, up 106.13% from the prior year.
• Net Cash Flow was -$7.4 million for Q1 2026 at Pacific Biosciences Of California, down from $7.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $176.4 million in Q3 2023 to a low of -$205.7 million in Q4 2023.
• Historically, Net Cash Flow has averaged -$24.0 million across 5 years, with a median of -$6.0 million in 2022.
• Biggest YoY gain for Net Cash Flow was 3033.48% in 2023; the steepest drop was 1096.02% in 2023.
• A 5-year view of Net Cash Flow shows it stood at $20.7 million in 2022, then plunged by 1096.02% to -$205.7 million in 2023, then surged by 89.01% to -$22.6 million in 2024, then soared by 130.78% to $7.0 million in 2025, then sank by 206.25% to -$7.4 million in 2026.
• The last three Net Cash Flow figures came in at -$7.4 million (Q1 2026), $7.0 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.